Quantcast

Latest Bristol-Myers Squibb Stories

2014-04-30 11:01:45

The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine. The...

2014-04-29 20:23:44

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.htmlIn recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S.,...

2014-04-29 12:34:11

SAN DIEGO and TAIZHOU CITY, China, April 29, 2014 /PRNewswire/ -- Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code: 600267) today announced a collaboration for the development and commercialization of bispecifics based on Ambrx technology for the treatment of cancer. Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun...

2014-04-24 08:34:30

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 24, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited...

2014-04-14 11:03:19

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of...

2014-04-07 16:25:29

SAN DIEGO, April 7, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of Ian B. Walters, M.D., MBA., a translational oncology and immunology expert. Dr. Walters was most recently an executive at Bristol Myers Squibb (BMS) where he led oncology drug development programs, large international matrix teams, and strategic transactions. He...

2014-04-04 12:27:03

SAN DIEGO, April 4, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq(TM) and Abraxane(®) (nab-paclitaxel) pharmacokinetics (PK) from animal studies. The PK data will be presented by Dr. Kouros Motamed, Vice President of Clinical Development & Nanomedicine on April 9 from 8:00 AM to...

2014-04-01 00:21:53

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer. The registration trial referred to as TRIBECA(TM) (TRIal designed to evaluate BioEquivalence...

2014-03-31 12:28:46

Innovative Physician Executive Brings Breadth of Healthcare Experience LOS ANGELES, March 31, 2014 /PRNewswire/ -- Health economics and policy authority Precision Health Economics (PHE) announced today the hiring of Ross Maclean as chief operating officer (COO). Dr. Maclean's significant and varied background spans the provider, payer, and manufacturing worlds in multiple countries, encompassing leadership skills, management talents, and a rapid career progression. His well-rounded...

2014-03-28 12:26:07

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/cw7xqm/investigation) has announced the addition of the "Investigation Report on China's Aripiprazole Market, 2009-2018" [http://www.researchandmarkets.com/research/cw7xqm/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Schizophrenia is a common mental disorder. Data shows that mental illness has...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related